The Scientist

» biotech

Most Recent

image: Flux and Uncertainty in the CRISPR Patent Landscape

Flux and Uncertainty in the CRISPR Patent Landscape

By | October 1, 2017

The battle for the control of the intellectual property surrounding CRISPR-Cas9 is as storied and nuanced as the technology itself.

0 Comments

image: Was a Drop in CRISPR Firms’ Stock Warranted?

Was a Drop in CRISPR Firms’ Stock Warranted?

By | June 7, 2017

A study of off-target effects that sparked fear among investors of genome-editing companies receives methodological criticisms.

5 Comments

image: CAR T-Cell Trials Boast Promising Results

CAR T-Cell Trials Boast Promising Results

By | June 6, 2017

The results of two small clinical trials show that the immunotherapy is effective for multiple myeloma patients, at least in the near term.

0 Comments

image: Learning from Iceland’s Model for Genetic Research

Learning from Iceland’s Model for Genetic Research

By | June 1, 2017

The Scandinavian island’s unique combination of genetic homogeneity, genealogical tradition, and high participation in research make it a prime location for discovery and validation of drug targets.

1 Comment

image: Former Head of Genzyme Dies

Former Head of Genzyme Dies

By | May 15, 2017

Henri Termeer helped usher the biotech company into an industry behemoth.

0 Comments

image: Life Science Leaders Meet at White House

Life Science Leaders Meet at White House

By | May 8, 2017

Heads of academia and industry mingled with the vice president and the secretary of Health and Human Services at a biotech summit.

0 Comments

image: Opinion: Preparing for Potential Disasters

Opinion: Preparing for Potential Disasters

By | January 25, 2017

How to increase the resiliency of biotechnology organizations in the face of emergency risks

0 Comments

On Tuesday, shareholders at the agribusiness giant approved the $66 billion deal with the European pharmaceutical firm.

0 Comments

image: Oligonucleotide Therapeutics Near Approval

Oligonucleotide Therapeutics Near Approval

By | December 1, 2016

Successful late-stage clinical trials could mark the maturation of a new drug development platform, but the path to commercialization is not without hurdles.

0 Comments

image: Another CRISPR Biotech Goes Public

Another CRISPR Biotech Goes Public

By | September 12, 2016

CRISPR Therapeutics, the company started by a pioneer of the gene editing technology, plans to raise $90 million from an initial public offering.

0 Comments

Popular Now

  1. GM Mosquitoes Closer to Release in U.S.
  2. Effects of Neanderthal DNA on Modern Humans
  3. Flux and Uncertainty in the CRISPR Patent Landscape
  4. Do Pathogens Gain Virulence as Hosts Become More Resistant?
RayBiotech